Oxford Biomedica (OXB) investor relations material

Strategic positioning and market opportunity

• Focused exclusively on Cell and Gene Therapy as a pure play, innovation-led CDMO with a competitive advantage in viral vector manufacturing.

• State-of-the-art facilities in the U.S., U.K., and France provide scalable capacity and proximity to major client clusters.

• U.S. expansion is prioritized due to its large market, client proximity, and favorable geopolitical and tax conditions.

• Acquisition of an FDA-approved Durham site accelerates U.S. growth and enhances end-to-end service capabilities.

• Facility network offers flexibility, resilience, and the ability to balance regulatory and supply chain risks.

Commercial performance and portfolio development

• Signed orders rose from GBP 56 million to over GBP 149 million in H1 2025, a 160% increase.

• 80% of contracts are from existing clients, with new business mainly in AAV; business is becoming more international.

• Portfolio supports over 40 client programs, with growth in both early- and late-stage clinical projects.

• Five late-stage programs are expected to transition to commercial in the coming years.

• Sufficient capacity exists for future commercial launches, with room for expansion at Oxford and Durham sites.

Innovation and operational excellence

• Innovation is client-centric, focusing on vector engineering, process improvements, AI-driven analytics, and automated batch release.

• AI and machine learning are being integrated to enhance yield, quality, and speed.

• Operational progress includes manufacturing optimization and increased capacity across regions.

• Revenue increased over 40% in H1 2025, with EBITDA loss narrowing to GBP 8.3 million.

• Financial flexibility strengthened by a $125 million loan and GBP 60 million equity raise.